FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308012977> ?p ?o ?g. }

• W4308012977 endingPage "1722" @default.
• W4308012977 startingPage "1715" @default.
• W4308012977 abstract "Objective Several studies have shown an increased risk of bullous pemphigoid (BP) when receiving dipeptidyl pepitidase-4 inhibitor (DPP-4i) treatment. The present study explored the associations of DPP-4i treatment with the clinical phenotypes and clinical course of BP. Methods We analyzed data of 146 patients with BP at Tokai University School of Medicine from December 1, 2009, to December 31, 2021. We obtained data by a retrospective medical record review and compared the bullous pemphigoid disease area index (BPDAI) between diabetes patients receiving DPP-4i treatment and those not receiving DPP-4i treatment. We employed multivariable linear regression models to explore the association between the DPP-4i treatment and the BPDAI scores. Results Among 53 BP patients with diabetes, 33 had developed BP during treatment with DPP-4i agents, among which vildagliptin was the most frequently used. The urticaria/erythema scores of the BPDAI were significantly lower in patients who developed BP while receiving DPP-4i treatment than among others. Of note, 69.2% of the patients who stopped DPP-4i treatment experienced complete remission, and the clinical course was more favorable in patients with lower scores for urticaria/erythema than among others. Conclusion These findings suggest that, in patients who developed BP while receiving DPP-4i treatment, a noninflammatory phenotype may indicate a high likelihood that DPP-4i treatment contributes to the development of BP. The discontinuation of DPP-4i should be carefully considered in close consultation with dermatologists." @default.
• W4308012977 created "2022-11-07" @default.
• W4308012977 creator A5023844335 @default.
• W4308012977 creator A5027404343 @default.
• W4308012977 creator A5064421797 @default.
• W4308012977 creator A5067154045 @default.
• W4308012977 creator A5085290238 @default.
• W4308012977 creator A5086207773 @default.
• W4308012977 creator A5089711554 @default.
• W4308012977 date "2023-06-15" @default.
• W4308012977 modified "2023-10-05" @default.
• W4308012977 title "Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center" @default.
• W4308012977 cites W1962185386 @default.
• W4308012977 cites W1995566056 @default.
• W4308012977 cites W1997885754 @default.
• W4308012977 cites W2015735533 @default.
• W4308012977 cites W2027223556 @default.
• W4308012977 cites W2028927085 @default.
• W4308012977 cites W2054438253 @default.
• W4308012977 cites W2071885971 @default.
• W4308012977 cites W2109688740 @default.
• W4308012977 cites W2113309969 @default.
• W4308012977 cites W2155692205 @default.
• W4308012977 cites W2158136745 @default.
• W4308012977 cites W2160461278 @default.
• W4308012977 cites W2164385416 @default.
• W4308012977 cites W2288299997 @default.
• W4308012977 cites W2333003991 @default.
• W4308012977 cites W2338042410 @default.
• W4308012977 cites W2395548559 @default.
• W4308012977 cites W2460874082 @default.
• W4308012977 cites W2528577049 @default.
• W4308012977 cites W2547580314 @default.
• W4308012977 cites W2616456969 @default.
• W4308012977 cites W2766698326 @default.
• W4308012977 cites W2772190174 @default.
• W4308012977 cites W2785773046 @default.
• W4308012977 cites W2789968638 @default.
• W4308012977 cites W2793163074 @default.
• W4308012977 cites W2819950008 @default.
• W4308012977 cites W2935961623 @default.
• W4308012977 cites W2953242146 @default.
• W4308012977 cites W2998492675 @default.
• W4308012977 cites W3036790608 @default.
• W4308012977 cites W4211003831 @default.
• W4308012977 doi "https://doi.org/10.2169/internalmedicine.0815-22" @default.
• W4308012977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36328578" @default.
• W4308012977 hasPublicationYear "2023" @default.
• W4308012977 type Work @default.
• W4308012977 citedByCount "0" @default.
• W4308012977 crossrefType "journal-article" @default.
• W4308012977 hasAuthorship W4308012977A5023844335 @default.
• W4308012977 hasAuthorship W4308012977A5027404343 @default.
• W4308012977 hasAuthorship W4308012977A5064421797 @default.
• W4308012977 hasAuthorship W4308012977A5067154045 @default.
• W4308012977 hasAuthorship W4308012977A5085290238 @default.
• W4308012977 hasAuthorship W4308012977A5086207773 @default.
• W4308012977 hasAuthorship W4308012977A5089711554 @default.
• W4308012977 hasBestOaLocation W43080129771 @default.
• W4308012977 hasConcept C126322002 @default.
• W4308012977 hasConcept C134018914 @default.
• W4308012977 hasConcept C159654299 @default.
• W4308012977 hasConcept C16005928 @default.
• W4308012977 hasConcept C203014093 @default.
• W4308012977 hasConcept C207103383 @default.
• W4308012977 hasConcept C2776453732 @default.
• W4308012977 hasConcept C2777180221 @default.
• W4308012977 hasConcept C2778075117 @default.
• W4308012977 hasConcept C2778715236 @default.
• W4308012977 hasConcept C2778763485 @default.
• W4308012977 hasConcept C2779252107 @default.
• W4308012977 hasConcept C2779306644 @default.
• W4308012977 hasConcept C2780031085 @default.
• W4308012977 hasConcept C2780323712 @default.
• W4308012977 hasConcept C44249647 @default.
• W4308012977 hasConcept C555293320 @default.
• W4308012977 hasConcept C71924100 @default.
• W4308012977 hasConcept C90924648 @default.
• W4308012977 hasConceptScore W4308012977C126322002 @default.
• W4308012977 hasConceptScore W4308012977C134018914 @default.
• W4308012977 hasConceptScore W4308012977C159654299 @default.
• W4308012977 hasConceptScore W4308012977C16005928 @default.
• W4308012977 hasConceptScore W4308012977C203014093 @default.
• W4308012977 hasConceptScore W4308012977C207103383 @default.
• W4308012977 hasConceptScore W4308012977C2776453732 @default.
• W4308012977 hasConceptScore W4308012977C2777180221 @default.
• W4308012977 hasConceptScore W4308012977C2778075117 @default.
• W4308012977 hasConceptScore W4308012977C2778715236 @default.
• W4308012977 hasConceptScore W4308012977C2778763485 @default.
• W4308012977 hasConceptScore W4308012977C2779252107 @default.
• W4308012977 hasConceptScore W4308012977C2779306644 @default.
• W4308012977 hasConceptScore W4308012977C2780031085 @default.
• W4308012977 hasConceptScore W4308012977C2780323712 @default.
• W4308012977 hasConceptScore W4308012977C44249647 @default.
• W4308012977 hasConceptScore W4308012977C555293320 @default.
• W4308012977 hasConceptScore W4308012977C71924100 @default.
• W4308012977 hasConceptScore W4308012977C90924648 @default.
• W4308012977 hasIssue "12" @default.

• next